Background: The International Association for the Study of Lung Cancer proposed the eighth edition of TNM classification of lung cancer on the basis of a new database in 2015. One of the most significant change in new criteria was that M descriptors has changed from three (M0, M1a and M1b) to four (M0, M1a, M1b and M1c). Although the 8th TNM classification is strong in the related with non-small cell lung cancer (non-SCLC) management, association between the 8th TNM classification and prognosis of SCLC patients remains unclear. In this study, we evaluated the applicability of the 8th TNM staging system to SCLC patients, especially whether prognosis of extensive disease (ED)-SCLC was related to the M descriptors. Method: We performed a retrospective study of consecutive 277 SCLC patients who had treated at our hospital between January 2008 and December 2016. The SCLC patients classified based on the 8th TNM classification and evaluated clinical factors and survival. Result: 186 (65.7%) of 277 SCLC patients were classified ED-SCLC based on the two-stage system, classically. Among the ED-SCLC patients, 10 (5.3%), 38 (20.4%), 32 (17.2%) and 106 (57.0%) were categorized into stage M0, M1a, M1b and M1c based on the 8th TNM classification, respectively. All ED-SCLC patients received systemic chemotherapy and median overall survival (OS) was 13.7 months. There were significant differences in OS [7.3 months; 95% confidence interval (CI), 5.7e8.9 months vs. 16.0 months; 95% CI, 13.2e18.8 months; p<0.001] according to the M descriptors (M0, M1a, M1b vs. M1c) and the TNM stage groups (III and IVa vs. IVb). Multivariate survival analyses showed that the M descriptor was one of prognostic factors (hazard ratio 1.50; 95% CI, 1.26e1.78 months; p<0.001) in addition to known prognostic factors such as ECOG performance status and pretreatment serum level of LDH. Conclusion: In this study, the 8th TNM classification had prognostic value in the SCLC patients treated with systemic chemotherapy. We suggested that ED-SCLC patients was divided into two subgroups based on the TNM classification. In ED-SCLC as well as non-SCLC, treatment development should be considered based on the TNM classification.
P3.12-17 A Retrospective Study Examining the Role of PET-CT in the 8th TNM Staging System of SCLC S. Tendler, V. Grozman, R. Lewensohn, G. Tsakonas, K. Viktorsson, L. De Petris Dept of Oncology-Pathology, Karolinska Institutet, Stockholm/SE Background: We have recently performed a validation of the 8th TNM system in SCLC. The aim of the present study is to perform a subgroup analysis on patients (pts) who underwent a PET/CT scan, to further assess potential utility of this method in SCLC pts, since PET/CT is usually performed primarily to identify potentially curable cases. Method: Between January 2008 and February 2016, a total of 706 pts with SCLC were diagnosed in the Stockholm and Gotland region. A multivariate model adjusted for basic patient characteristics and PET-CT was performed. Result: One third of the patients had performed a PET/CT scan (n¼204). Pts were classified according to the 8th TNM. The table shows patient distribution according to clinical variables and stage (8th TNM), as well as HR for multivariate survival analysis. Many pts (48%) were classified to stage I-III disease, while the rest had stage IV. Pts with stage I-III were treated with Surgery (n¼13), Radio-therapy+ Chemotherapy (CT) (n¼80) or Stereotactic body radiation (n¼7). The patients who were diagnosed with stage IV disease were treated with palliative CT or did not receive any oncological therapy. In pts that did not perform PET/CT, the majority (87%) were treated with CT or did not receive treatment. The percentage of pts diagnosed with M1b-disease was slightly higher in those who performed a PET/CT vs those who did not (7% vs 3%, respectively). Conclusion: The 8th TNM edition has a strong prognostic impact in SCLC. Incorporating a PET/CT scan in the diagnostic workup of SCLC is relevant to distinguish potentially curable pts (stages I-III) from pts with stage IV disease, and may be of value to indentify single extra-thoracic metastases (M1b cases). Keywords: SCLC, PET/CT P3.13-01 Detecting ALK Rearrangements in NSCLC Patients: IHC, FISH or NGS Fusion?
A. Addeo, A. Friedlander, C. Py, P. Dietrich Hug, Genève/CH Background: Rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small cell lung cancer (NSCLC) represent a novel molecular target in a small subset of patients. Although ALK rearrangements are usually assessed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), molecular approaches have recently emerged as relevant alternatives in routine laboratories. Previous studies that compared FISH and IHC considered FISH the gold standard, although there are emerging data on ALK fusion variants that question the role of FISH. Method: Here, we report our personal experience with the use of the IHC, FISH and next-generation sequencing (NGS) analyses in a group of ALK rearranged NSCLC patients treated within our institution Result: A total of 13 patients with NSCLC was positive for ALK rearrangements on IHC and was subsequently tested with FISH. Interestingly 5 out of 13 patients were negative on FISH but all the patients received first line ALK inhibitors. The response rate (RR) was 79% (10/13), the progression free survival (PFS) was 19 months for the total population. Among the non-responders 2/13 were FISH negative but 1/13 was IHC and FISH positive. We are going to retrospectively perform NGS analyses to further assess the role of NGS fusion in the context of ALK patients. Conclusion: Our study suggests that IHC is a valid, quick and reliable assay for the detection of ALK gene rearrangements. It also shows that FISH should not be considered the gold standard on its own for the detection of ALK gene rearrangements. We are going to present the data on NGS fusion in this group of patients at the next conference (WLLC November 2018) with the view of seeing if NGS fusion could and should be a valid alternative and replace FISH as the gold standard. Keywords: ALK, IHC, NGS fusion
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